AVEO Pharmaceuticals Inc

AVEO Oncology, listed here as AVEO Pharmaceuticals, is a Cambridge biopharmaceutical company focused on cancer medicines that let patients carry on with daily life during treatment. Its lead product is tivozanib, sold as FOTIVDA, a selective, long-acting inhibitor of the VEGF 1, 2 and 3 receptors used to treat advanced renal cell carcinoma. The company’s portfolio includes both medicines on the market and candidates in development, in the United States and globally.

AVEO operates as an LG Chem company. Under the partnership, LG Chem Life Sciences concentrates on pre-clinical and early clinical development, while AVEO oversees late-stage clinical development in the United States and uses LG Chem’s resources to bring new cancer drugs to market, extending LG Chem’s commercial reach into the United States. Its pipeline has included ficlatuzumab for head and neck cancer and earlier-stage antibodies such as AV-203, AV-380 and AV-353. A Scientific Advisory Committee of oncology experts advises the company.

What to Know

• Tivozanib is approved by the European Commission for adult patients with advanced renal cell carcinoma.
• AVEO actively seeks partnerships with other pharmaceutical and biotech companies in oncology.
• The leadership team is made up of experienced pharmaceutical industry executives.
• The company is listed with the Central Square Business Improvement District.